The role of dyslipidemia and statins in venous thromboembolism

Joel G. Ray; Frits R. Rosendaal

doi:10.1186/cvm-2-4-165

Article2001

Review The role of dyslipidemia and statins in venous thromboembolism

Joel G. Ray, Frits R. Rosendaal

Article2025

Lipoprotein(a) and Venous Thromboembolism: Association, Causality, and Medications

Mariana Pfeferman, Sina Rashedi, Professor Gregory Lip, C. Weber, Michelle L. O’Donoghue, Steven E. Nissen, Stephen J. Nicholls, Pradeep Natarajan, Jorge Plutzky, Peter Libby, Samuel Z. Goldhaber, Gregory Piazza, Behnood Bikdeli

Article2025

Prevalence of cardiovascular risk factors in persons with venous thromboembolism aged fifty years or younger

Eng Soo Yap, Frits R. Rosendaal, Suzanne C. Cannegieter, Luuk J.J. Scheres

Deleted Journal

Article2003

HMG-CoA Reductase Inhibitors Regulate Inflammatory Transcription Factors in Human Endothelial and Vascular Smooth Muscle Cells

Wolfgang Dichtl, Jozef Dulak, Matthias Frick, Hannes Alber, Severin P. Schwarzacher, Mikko P.S. Ares, Jan Nilsson, Otmar Pachinger, Franz Weidinger

Article1997

Prevention of venous thromboembolism in high risk patients.

Giancarlo Agnelli, Francesco Sonaglia

The role of dyslipidemia and statins in venous thromboembolism

Abstract

Discussion(0)

Related publications

Review The role of dyslipidemia and statins in venous thromboembolism

Lipoprotein(a) and Venous Thromboembolism: Association, Causality, and Medications

Prevalence of cardiovascular risk factors in persons with venous thromboembolism aged fifty years or younger

HMG-CoA Reductase Inhibitors Regulate Inflammatory Transcription Factors in Human Endothelial and Vascular Smooth Muscle Cells

Prevention of venous thromboembolism in high risk patients.